Prana Biotechnology mentioned cautiously at Summer Street Summer Street said it believes Prana Biotechnology 's PBT2 is a "long shot" as a treatment for Alzheimer’s and Huntington’s diseases. The firm is skeptical about PBT2's proposed mechanism. Shares of Prana are trading down 57c to $9.35 in pre-market trading.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.